The Emerging Landscape of Psychedelic Therapy: Education and Certification

The field of psychedelic therapy is witnessing a resurgence, driven by growing evidence of its potential to treat mental health conditions like PTSD, depression, and anxiety. As interest surges, so does the need for comprehensive education and certification programs to ensure that therapists are well-prepared to administer these powerful substances safely and effectively. This article delves into the current state of training and certification for psychedelic therapists, highlighting key insights from industry experts and exploring the complexities of this emerging field.

The Current State of Training and Certification Programs

Dustin Robinson, founding manager of Iter Investments and co-founder of Mr. Psychedelic Law, emphasizes the varied training needs within the psychedelic community. “People are seeking training on various aspects of psychedelics,” Robinson notes. “Some have higher degrees and want training for delivering psychedelics in a clinic once these compounds are approved by the FDA; others simply want to hold space for individuals outside of the medical context.”

This diversity underscores a significant challenge: matching individuals with appropriate training programs. To address this, Robinson’s team launched Neuly Edu, a platform designed to help prospective therapists find the right courses for their specific needs. Another notable program is the Science of Psychedelics, an accredited online course offering seven comprehensive modules covering topics like microdosing, MDMA, ketamine, and psychedelic counseling. It provides healthcare professionals with in-depth knowledge and certification in the clinical applications of psychedelics.

The legal landscape surrounding psychedelics is complex, and Robinson stresses the importance of consulting with attorneys when developing training curricula. “There are various disclaimers training companies should have, and certain types of content are higher risk,” he explains. Ensuring ethical and regulatory compliance is crucial, particularly for training conducted outside of a medical context.

Mr. Psychedelic Law focuses on state legal reform, drafting legislation that outlines training requirements for psychedelic facilitators. “Both Oregon and Colorado have very specific requirements around the training required for facilitators, and we expect other states to follow suit,” Robinson states. Balancing high standards with accessibility is key to ensuring safe and effective treatment.

Jeff McNairy, Psy.D., M.P.H., Chief Medical Officer of Rythmia Life Advancement Center, highlights the essential qualities for guiding psychedelic journeys. “Successful guides are open-minded, empathic caregivers with clear personal boundaries,” McNairy explains. “They must also have a basic knowledge of diagnostic psychological criteria and recognize acute symptoms relevant to the psychedelic experience.”

Rythmia integrates daily classes to help guests process their experiences post-ceremony. McNairy elaborates, “Every guest receives a login code for a free integration application called ‘R-Life,’ which includes weekly group therapy sessions and additional resources to aid in their integration process.”

While beneficial, first-hand experience with psychedelics is not deemed essential by McNairy. “It’s not necessary for a therapist to have consumed psychedelics themselves, though it can be helpful. The key is allowing the client’s experience to be unique and not overly influenced by the facilitator.”

“At the core of integrative psychedelic-assisted therapy is the understanding that the mind and body are intrinsically connected. As therapists, we must be willing to explore that connection within ourselves through direct experience in order to truly grasp the profound healing potential these medicines offer. Having one’s own psychedelic journey allows therapists to be aware of the subtle nuances a patient may need support with and be present for the  psychedelic experience in a way that simply isn’t possible through intellectual understanding alone. When we have insights into   our own transcendental experiences and non-ordinary states of consciousness, we become better guides for our patients as they navigate their own psychedelic-assisted journeys of self-discovery and inner healing. This first-hand experience cultivates an embodied awareness that strengthens the therapeutic alliance and our ability to compassionately support and be   in service of our patients’ highest aspirations.” – Shari B. Kaplan LCSW, Clinical Director, Cannectd Wellness

Attorney Paula Savchenko, Esq., founder of Cannacore Group, discusses the legal hurdles in establishing certification pathways across different states. “State agencies must ensure certification programs uphold best practices, especially given the heightened vulnerability of patients during and after psychedelic sessions,” Savchenko explains. The evolving regulatory landscape demands robust training and continuous education to keep facilitators current with new developments.

Savchenko notes the burgeoning demand for trained psychedelic therapists. “With only a few states currently implementing regulated psychedelic markets, the need for licensed therapists is skyrocketing. Entering the market now allows therapists to gain valuable experience that sets them apart.”

Numinus Training offers a structured certification pathway for diverse professionals seeking to provide psychedelic-assisted therapy. Their programs, accredited by several professional bodies, blend interactive learning with experiential opportunities.

“It’s an exciting time in the world of training for psychedelic-assisted therapy. The Canadian-based traded company, Numinus has been building clinical expertise and developing training for several years. This year, they welcomed Rick Doblin as their Strategic Advisor. “We are honored to welcome Dr. Rick Doblin to Numinus as an unpaid strategic adviser. His wealth of experience and commitment to the advancement of psychedelic-assisted therapies align seamlessly with Numinus’ mission to provide transformative and accessible care to individuals worldwide,” said Payton Nyquvest, Numinus Founder and CEO.

This announcement came on the heels of the pending FDA approval of the “first of its kind” experiential learning opportunity for trainees to experience MDMA as a part of their training. If approved, Numinus intends to make the experiential learning opportunities available to practitioners as part of its psychedelic-assisted therapy education and training certification pathway. This approval could come as early as July 2024. Numinus will also be creating a fast-track pathway for practitioners who have already completed robust psychedelic-assisted therapy programs, including the MAPS MDMA training programs that were previously offered.

This is a huge step forward in advancing efficacy of treatment and the availability of these medicines. LYKOS will still need to approve and license the clinics for the distribution of MDMA once the legalization takes place, but Numinus is preparing the leaders of tomorrow to get the training they need to deliver these healing opportunities. At this time, only licensed professionals will be eligible to complete the experiential portion but unlicensed practitioners can do the remote coursework to build skills to serve as a secondary sitter for medicine work alongside a licensed professional.

The first step for all practitioners looking for certification is Numinus’ 10- week Fundamentals of Psychedelic-Assisted Therapy program. The Numinus team aligns its curriculum to the most up to date competency and legislative requirements to help ensure the providers have what they need to deliver safe and effective care. In August, when they run their next Fundamentals of PAT cohorts, all learners will get the opportunity to experience an experiential learning ceremony, helping to build skills with group facilitation work.

This is an exciting time. The speed at which psychedelic-assisted therapies have been made available has been lightning-fast compared to other mental health and treatment interventions. At the 2023 MAPS Psychedelic Science Conference, Steve DeAngelo stated that the only thing he would have done differently is to accept medicalization earlier, so cannabis could have been more widely accessible to more people in need faster. Luckily, the Psychedelic movement has learned from its predecessors.”

Kathryn A. Walker, MSN-Anesthesia, MSN-Psychiatry CEO at Revitalist Lifestyle and Wellness (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO), Shari B. Kaplan, LCSW Integrative Mental Health Clinician at Cannectd Wellness, and Dr. Michelle E. Weiner, DO, MPH praised the Numinus training for its thoroughness and practical applications.

As the field of psychedelic therapy continues to grow, the need for comprehensive and standardized training programs becomes increasingly critical. By addressing diverse training needs, ensuring ethical and regulatory compliance, and providing robust certification pathways, organizations like Neuly Edu, Mr. Psychedelic Law, Numinus, and the Science of Psychedelics course are paving the way for the next generation of psychedelic therapists. These efforts will help ensure that psychedelic therapy is safe, effective, and accessible to those who need it most.